Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell: remember the myth of Icarus re the current steep incline

October 25, 2018 9:06pm

Don’t get too lathered-up over today’s incline as I had stated, “The downside influence is not over.”

Pre-open indications: 4 HITs and 1 MISS

Q3 results: BioMarin Pharmaceuticals (BMRN+$3.55 or +3.82%) reported a loss of $12.6 million or a per share loss of -$0.07 in its Q3. Earnings, adjusted for stock option expense, came to $0.14 cents per share.

Who is reporting the metrics for individual investors?

RMi’s daily report may say little or a lot and its final judgement may be inconclusive; yet it serves as insurance that all indications are being examined and evaluated.

While many talk about the shift in alternating sentiment, I monitor the pulse and focus of possible outcomes ...

Daily analytics and metrics:

The Dow closed up +401.13 points or +1.63% to 24,984.55
The S&P closed up +49.47 points or +1.86% to 2,705.57
The NASDAQ closed up +209.93 points or +2.95% to 7,318.34

The advance/decline line scenario of 45 covered companies:

The open was positive with an A/DL of 39/4 and 2 flats;
The mid-day was positive with an A/DL of 38/5 and 2 flats;
The close was positive with an A/DL of 37/7 and 1 flat;

Pre-open indications: 4 HITs and 1 MISS

CRISPR Therapeutics (CRSP) closed up +$1.32 – hit;
Intellia Therapeutics (NTLA) closed up +$0.87 – hit;
Athersys (ATHX) closed up +$0.03 – miss;
BioLife Solutions (BLFS) closed up +$0.61 – hit;
Sangamo Therapeutics (SAGE) closed up +$0.37 – hit;

Quarterly results:

BioMarin Pharmaceuticals (BMRN +$3.55 or +3.82%) - reported a loss of $12.6 million or a per share loss of -$0.07 in its Q3. The results topped “Street” expectations.

The results had street expectations for earnings of $0.13 per share. BMRN posted revenue of $391.7 million in the period, which also topped “street” forecasts with an expectation of $369.4 million. BMRN expects full-year revenue in the range of $1.47 to $1.53 billion. BioMarin shares have risen 8% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $96.43, a climb of 14% in the last 12 months.

Five (5) key metrics:

… The greatest volume to the downside: BLCM, PSTI, CLLS, AST and FIXX

… Upside volume was weighted to: HSGX, CUR, SGMO, MDXG and VSTM

… Leadership ($) to the downside: OSIR (-$0.400, CLLS (-$0.20), FIXX (-$0.17), BLCM (-$0.09) and AGTC (-$0.03)

… Best moves ($) to the upside: RGNX (+$6.56), DAGE (+$5.840, ALNY (+$4.920, BLUE (+$4.35) and RARE (+$4.31)

… The iShares NASDAQ Biotechnology (IBB) closed:

Thursday was up +1.15% after NOT indicating a POSITIVE +0.7% in the pre-market;
Wednesday was down -5.76% after indicating a NEGATIVE -0.59% in the pre-market;
Tuesday was down -0.48% after NOT indicating in the pre-market;
Monday was down -1.44% after indicating a POSITIVE +0.01% in the pre-market;
Friday was down -1.58% after NOT indicating in the pre-market;
Last Thursday was down -1.47% after NOT indicating in the pre-market;

Henry’omics:

What happened yesterday was the market got way oversold – even a blind man could see the change yet, with EVERY correction – there is an invisible hand!

This is much more of a sentiment shift than a fundamental shift …

Sector equities jumped on Thursday as indexes recovered from a tumble in the previous session that even sent two of the major indexes into the red for 2018.

Thursday is the first day of the earnings season for my cadre of companies – let the LPS (loss-per-share) quarterly results … begin!

Review the range of the 37 upside from +0.62% (BCLI) to or +17.68% (FATE) while the 7 downside ranges from 0.46% (AGTC) to -3.79% (OSIR) with a 1 flat close (RENE.L).

Interesting stat: Volume INCREASED … look at the depth – 20 out of 37 of the upside had higher (than the 3 month average) volume while 2 of the downside experienced greater volume (than the 3 month average) out of 7.

From the pre-open newsletter, “… like the ashes of the Phoenix, the sector rise. Most sector equities will rise from the week’s crashes yet; I wouldn’t rush the BUY ticket. The downside influence is not over.”

October sessions:

Thursday closed POSITIVE with 7 decliners, 37 advancers and 1 flat;

Wednesday closed NEGATIVE with 41 decliners, 3 advancers and 1 flat;

Tuesday closed NEGATIVE with 23 decliners, 21 advancers and 1 flat;

Monday closed NEGATIVE with 33 decliners, 11 advancers and 1 flat;

Friday closed NEGATIVE with 34 decliners, 8 advancers and 3 flat;

Thursday closed NEGATIVE with 36 decliners, 8 advancers and 1 flat;

Wednesday closed NEGATIVE with 25 decliners, 19 advancers and 1 flat;

Tuesday closed POSITIVE with 4 decliners, 39 advancers and 2 flats;

Monday closed NEGATIVE with 26 decliners, 17 advancers and 2 flats;

Friday closed POSITIVE with 9 decliners, 35 advancers and 1 flat;

Thursday closed NEGATIVE with 38 decliners, 7 advancers and 0 flat;

Wednesday closed NEGATIVE with 42 decliners, 2 advancers and 1 flat;

Tuesday closed NEGATIVE with 23 decliners, 18 advancers and 4 flats;

Monday closed NEGATIVE with 34 decliners, 10 advancers and 1 flat;

Friday closed NEGATIVE with 26 decliners, 17 advancers and 2 flat;

Thursday closed NEGATIVE with 35 decliners, 8 advancers and 2 flat;

Wednesday closed POSITIVE with 16 decliners, 27 advancers and 2 flat;

Tuesday closed NEGATIVE with 32 decliners, 12 advancers and 1 flat

Monday (10/1) closed NEGATIVE with 33 decliners, 13 advancers and 1 flat;

In 19 sessions in September – there were 10 negative closes and 9 positive close;
In 21 August sessions – 6 had negative and 15 had positive closes

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

6 hours 28 min ago
RegMed Investors’ (RMi) pre-open: market, market and the sector pullbacks are driven by Israel retaliation against Iran tempered expectations for a rate cut

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.